Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Gemcitabine and Cisplatin

First Posted Date: 2010-12-16

Last Posted Date: 2025-01-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 57

Registration Number: NCT01261728

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Hartford Hospital (Data Collection Only), Hartford, Connecticut, United States

and more 6 locations

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Phase 1

Completed

Conditions: Bladder Cancer

Interventions: Drug: Everolimus and Intravesical Gemcitabine

First Posted Date: 2010-12-13

Last Posted Date: 2018-03-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT01259063

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation

Terminated

Conditions: Fibrillation
Post-Operative Cancer Patients Experiencing Atrial

Interventions: Behavioral: questionnaire about the use of ECG device

First Posted Date: 2010-12-03

Last Posted Date: 2015-03-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5

Registration Number: NCT01253590

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Phase 2

Completed

Conditions: Uveal Melanoma

Interventions: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR

First Posted Date: 2010-12-02

Last Posted Date: 2017-08-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT01252251

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Not Applicable

Terminated

Conditions: Breast Cancer

Interventions: Device: Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)

First Posted Date: 2010-11-29

Last Posted Date: 2015-12-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT01249157

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: carboplatin

First Posted Date: 2010-11-25

Last Posted Date: 2019-10-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 146

Registration Number: NCT01248962

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission

Phase 1

Completed

Conditions: Peritoneal Cancer
Ovarian Cancer
Fallopian Tubes

Interventions: Biological: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21

First Posted Date: 2010-11-25

Last Posted Date: 2017-03-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT01248273

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy

Terminated

Conditions: Breast Cancer

Interventions: Other: GlowCap device

First Posted Date: 2010-11-11

Last Posted Date: 2015-03-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT01239251

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Not Applicable

Completed

Conditions: Fallopian Tubes Cancer
Ovarian Cancer
Peritoneal Cancer

Interventions: Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821

First Posted Date: 2010-10-18

Last Posted Date: 2018-06-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT01223235

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy

Phase 3

Active, not recruiting

Conditions: Melanoma
CNS-Spinal CD/MEMBR, NOS
Soft Tissue
Sarcoma
Lymph Nodes
Ovarian Cancer
Bone

Interventions: Radiation: IGIMRT using a single dose of 24 Gy
Radiation: IGIMRT 27 Gy in 3 fractions

First Posted Date: 2010-10-18

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 220

Registration Number: NCT01223248

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇮🇹
University of Pisa, Pisa, Italy

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy